Key Points
-
Anthropic will soon go public.
-
It’s already investing in research automation for bioscience, including in robotics.
-
The company will continue to need a lot of collaborators for those purposes to accomplish its goals.
-
Ginkgo Bioworks offers a highly automated and AI-friendly research platform already.
-
Anthropic (NASDAQ:ANT) is planning to move forward with its initial public offering (IPO), with trading expected to begin Nov. 19. In doing so, the AI company will raise tens of billions of dollars, which it plans to spend on computing power and infrastructure. But with its focus increasingly turning toward orienting its AI capabilities toward bioscience, the next few years will likely see it make major investments to secure the ingredients it needs to test the hypotheses its AI proposes.
Chief among those ingredients are lab space and biomedical research equipment — and, as it’s a tech company bent on automation, laboratory robotics and other research automation solutions will be near the top of the list.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Enter Ginkgo Bioworks (NYSE:DNA), a lab-automation biotech and aspiring biomanufacturer that’s already collaborating with Anthropic’s biggest competitor, OpenAI. While many other businesses offer different components of an automated biopharma research stack, Ginkgo says its cart-based system is more modular, expandable, robust, and customizable than any competing platform on the market. So does Anthropic, and its soon-to-land massive pile of money make Ginkgo worth buying right now?
Image source: Getty Images.
Research automation is an expensive category
Ginkgo has a unique approach to developing a fully autonomous lab designed to handle multiple types of experiments with minimal hands-on time.
Its solution features a series of robotic carts, each with a central cabinet with an optional small sterile environment. They are connected so they can pass samples and data along after each experiment, while the software plans the next experiments. Humans set the system’s goals and check its results. Each cart typically has at least one piece of laboratory hardware in its cabinet, such as a liquid-handling robot, a centrifuge, or an analyzer. Ginkgo’s Nebula lab runs more than 100 of these reconfigurable carts.
OpenAI has already put one of its advanced models in charge of a Ginkgo lab. In OpenAI’s pilot program, GPT-5 took on the role of AI scientist, designing 36,000 small experiments over a period of six months that Ginkgo’s cart-based robots then ran while humans prepped the necessary reagents. Ultimately, the pilot program supposedly reduced the production cost of a test protein by 40%.
In third-quarter 2026, Ginkgo said frontier AI labs also use its cloud lab (lab work customers order remotely) for getting more training data, and it even sold its first autonomous lab to Novo Nordisk (NYSE:NVO). Still, its Q3 revenue fell 6% year over year to $28 million, and it reported a $41 million net loss from continuing operations. One important thing to remember here is that a large portion of early biopharma research is done manually, which means paying labor costs rather than capital expenditures for automation hardware.
Will Anthropic’s IPO send any business to Ginkgo?
Anthropic already has a bioscience laboratory, and it contracts out some of its physical scientific workload when it’s efficient to do so. For example, a muscular dystrophy program it recently acquired went on to coordinate experiments across 11 external labs. That’s a very high number of collaborators to juggle for a project in preclinical-stage research. Ginkgo could be competing to be one of those collaborators in the future, as contract research organizations (CROs) doubtlessly were and are.
However, Anthropic has no public ties to Ginkgo, unlike OpenAI. Its Model Hardware Standard, which is intended to enable AI agents to operate lab equipment, has eight vendor partners, including a lab-automation business called Automata, but not Ginkgo. Since that system is intended to work with any programmable device, it means rivals’ lab automation hardware would work just as easily as Ginkgo’s, making its capabilities a harder sell.
Anyone wanting upside from Anthropic’s biology push can buy its stock once it’s listed. It’s very possible that Ginkgo will work with Anthropic in the future. As of now, though, the upcoming IPO isn’t something to bank on for Ginkgo’s stock, and it doesn’t constitute a distinct reason to buy it yet.
Should you buy stock in Ginkgo Bioworks right now?
Before you buy stock in Ginkgo Bioworks, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ginkgo Bioworks wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $955,232!*
Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 18, 2026.
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Novo Nordisk. The Motley Fool has a disclosure policy.